Lapuz Carminia, Enjeti Anoop K, O'Brien Peter C, Capp Anne L, Holliday Elizabeth G, Gupta Sanjiv A
Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, NSW, Australia,
Faculty of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia,
Blood Lymphat Cancer. 2018 Apr 18;8:13-20. doi: 10.2147/BLCTT.S160404. eCollection 2018.
This study evaluated relapse patterns and survival in advanced Hodgkin lymphoma (HL) patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) with positron emission tomography (PET) used for staging and response assessment.
Patients aged 18 years or above with newly diagnosed histologically proven Stage III or IV HL treated with ABVD at Calvary Mater Newcastle from January 2005 to December 2012 were included in this study. All patients underwent pre-chemotherapy staging with F-fluorodeoxyglucose PET or PET/computed tomography and post-chemotherapy PET or PET/computed tomography for the assessment of response.
Forty-three patients were included in the study. The 5-year disease-free survival, progression-free survival and overall survival were 88%, 74% and 86%, respectively. PET complete response was seen in 35 patients (81%), and the 5-year overall survival for this group was 94%. Relapse following a PET complete response was low (three patients) and occurred predominantly at the initial sites of disease. Four of five patients with bulky disease received consolidative radiotherapy and no in-field relapses were observed.
Advanced stage HL with a PET complete response following ABVD is associated with an excellent prognosis.
本研究评估了采用阿霉素、博来霉素、长春花碱和达卡巴嗪（ABVD）治疗的晚期霍奇金淋巴瘤（HL）患者的复发模式和生存率，正电子发射断层扫描（PET）用于分期和疗效评估。
纳入2005年1月至2012年12月在纽卡斯尔加尔瓦里医院接受ABVD治疗的18岁及以上新诊断的组织学确诊为III期或IV期HL患者。所有患者在化疗前接受F-氟脱氧葡萄糖PET或PET/计算机断层扫描进行分期，并在化疗后接受PET或PET/计算机断层扫描以评估疗效。
43例患者纳入本研究。5年无病生存率、无进展生存率和总生存率分别为88%、74%和86%。35例患者（81%）出现PET完全缓解，该组5年总生存率为94%。PET完全缓解后的复发率较低（3例患者），且主要发生在疾病的初始部位。5例有大包块病变的患者中有4例接受了巩固性放疗，未观察到野内复发。
ABVD治疗后PET完全缓解的晚期HL患者预后良好。
